Zambon: Who We Are

A company's history lies in its heritage, rich in its values and makeup. It is a kind of DNA and rediscovering it serves as a natural link between this heritage and the present.

At a time when advances in technology and our hectic pace of life drive us to consume at breakneck speeds, it's important to take time to reflect, read and "breathe in" a part of our past, to recognize the value of the people and principles that they upheld and still now uphold.

To understand the "secrets" that lie behind the growth and have strengthened the Zambon group over the years, it is necessary not only to go back over the company's industrial and financial history but also to investigate the individual and collective values associated with them.
Zambon's history is made up not just of facts and figures but above all of one hundred years of a family history that is inextricably linked with its business to become one single entity.

1906
On 11 November, Gaetano Zambon opens the "Zambon Medicinal Warehouse" in Vicenza along with Silvio Farina.

1908
The company is named “Gaetano Zambon e C”.

1920
The company begins manufacture of Zambon galenic medicines.

1928
The company adopts the brand name “Zef”, taken from the names of the two partners: Gaetano Zambon and Silvio Farina.

1932/1933
Alongside the production of drugs, it also starts synthesizing raw materials.

1938
The first Zambon research laboratory opens in Vicenza.

1944
On 14 May, the Zambon plant is razed to the ground during the American bombing of Vicenza.

1946
The Zambon plant in Vicenza is rebuilt following its destruction. There are 550 employees.

1948
Alberto Zambon, 24 years old, son of Gaetano, takes over the company.

1956
The first plant in Brazil is built.

1960
The Spanish branch is set up. The Zambon laboratories synthesize N-acetylcysteine.

1961
The headquarters moves to Bresso along with the administrative offices and research laboratory. That same year relations with Japan begin and the company begins working with the EISAI company, which has a license to produce injectable chloramphenicol in Japan.

1963
The new production plant is opened in Cadempino.

1965
Inauguration in Lamone of the Swiss plant for Zambon products.

1965/1975
During this period, the Group begins its international expansion, opening branches in the main European countries and in Central and South America.

1979
Zambon's research identifies a new molecule: fosfomycin trometamol.

1985
From Zambon's research, a new molecular combination is developed: ibuprofen and arginine.

1995
Zambon opens offices in Russia and Hong Kong; a joint venture is agreed in China for the supply of N-acetylcysteine. The American FDA approves production of phosphonomycin trometamol for the US market.

2000
The Chinese plant in Haikou is inaugurated for Zambon products for the domestic market.

2003
New start-up companies developed Zcube, in innovative sectors.

2006
Zambon Group celebrates its Centenary.

2008
The Zambon Museum is opened.

2010
Zambon has a strong “External Manufacturing Management” network, an outsourced virtual production plant that involves more than 80 subcontractors worldwide

2012/2013
Zambon enters in two new therapeutic area: the one of Central Nervous System (CNS) with the molecule Safinamide for the treatment of Parkinson’s disease, as well as Rare Diseases with the acquisition from Philips of Profile Pharma for the treatment of Cystic Fibrosis.

2014
CHMP recommends Approval of XadagoTM (Safinamide) to treat Parkinson's disease in the EU.